Dr. Shi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2505 W Hammer Ln
Stockton, CA 95209Phone+1 209-957-7050
Education & Training
Valley Baptist Medical CenterResidency, Family Medicine, 2000 - 2003- OtherClass of 1985
Certifications & Licensure
CA State Medical License 2002 - 2026
TX State Medical License 2003 - 2007- American Board of Family Medicine Family Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- 64 citationsActivity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer CellsGottfried E. Konecny, Teodora Kolarova, Neil A. O'Brien, Boris Winterhoff, Guorong Yang
Molecular Cancer Therapeutics. 2013-05-01 - 2 citationsThe USCACA hosted symposiums at the 7th CACA annual meeting and the 15th CSCO annual meeting in Beijing.Michael Shi, Wancai Yang, Pascal Qian, Li Yan
Chinese Journal of Cancer. 2012-11-01 - Biomarker Development Strategies - surmounting scientific and regulatory barriers in bringing innovative medicine to market.Michael Shi
Idrugs. 2007-04-01
Press Mentions
Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022June 2nd, 2022- Transcenta Doses First Subject in Phase I Osteoporosis Drug Trial in ChinaApril 29th, 2022
- More Unique Therapeutic Possibilities Posed by Rare Human GenesMarch 14th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
